Silexion Therapeutics (SLXN)
Develops RNA-targeting treatment candidates for KRAS-mutated pancreatic cancer.
Something off on this page? Send us feedback.
Develops SIL204, an siRNA candidate for KRAS-mutated locally advanced pancreatic cancer, designed to degrade the messenger RNA that produces mutated KRAS proteins. The clinical-stage program uses intratumoral and subcutaneous dosing with chemotherapy and relies on external organizations for manufacturing and trial execution.
Develops SIL204, a small-interfering-RNA treatment designed to degrade messenger RNA that produces mutated KRAS proteins. Its initial program targets KRAS-mutated, locally advanced pancreatic cancer, pairing direct intratumoral and systemic subcutaneous dosing with standard chemotherapy. The approach grew from the earlier LODER program, now retained as a prototype rather than the commercial lead.
Operates as a clinical-stage research-and-development organization in Israel, with a German presence supporting trials and a largely inactive Chinese subsidiary. Clinical study authorization covers Israel and Germany, while site activation and enrollment remain ongoing. Manufacturing, clinical studies and material operations depend on external organizations; there is no approved product, product revenue or internal commercial infrastructure.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $2.2M · Total debt $1.4M · Total assets $4.2M · Shareholders' equity $44.0K
- Revenue
- $0
- Operating income
- −$3.7M
- Net income
- −$3.6M
No dividends on record.
| Institutions7 holders · as of Mar 31, 2026 | 0.07% | 3.6K shares | |
| Insiders9 holders · as of Jun 8, 2026 | 1.65% | 91.5K shares | |
| Otherremainder | 98.28% | 5.47M shares |
5.56M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (5.56M in the company's Sep 3, 2026 report, 419.0K elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Ilan LevinInsiderdirector, 10 percent owner | 0.82% | 45,697 | Form 4filed Jan 27, 2026 ↗ |
Ilan HadarInsiderdirector, officer: Chairman and CEO | 0.30% | 16,547 | Form 4filed Jun 8, 2026 ↗ |
Hadar Mirit HorenshteinInsiderofficer: CFO and Secretary | 0.23% | 12,515 | Form 4filed Jun 8, 2026 ↗ |
Mitchell ShirvanInsiderofficer: CSO and CDO | 0.16% | 8,789 | Form 4filed Jun 8, 2026 ↗ |
Avner LushiInsiderdirector | 0.05% | 2,540 | Form 4filed Feb 23, 2026 ↗ |
| See all 21 → | |||
Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Mar 26, 2026 | Mitchell Shirvan | officer: CSO and CDO | −22,818 | $1.36 |
- Revolution Medicines
Most direct RAS competitor in KRAS-mutant pancreatic cancer.
- Bristol-Myers Squibb
KRAS programs and pancreatic-trial resources overlap.
- Eli Lilly
Oral KRAS G12C program includes pancreatic-cancer cohorts.
- Amgen
Commercial KRAS inhibition adds protein-targeting pressure.
- Alnylam Pharmaceuticals
RNAi platform and delivery expertise compete for enabling capabilities.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Silexion Therapeutics | $0.3515 | +0.34% | $147.2K | — | — | — | — |
| Revolution Medicines | $211.87 | +1.26% | $44.48B | — | — | — | — |
| Bristol-Myers Squibb | $67.50 | −0.23% | $138.21B | 14.9 | 10.6 | 2.8 | +5.7% |
| Eli Lilly | $1,165.49 | +0.53% | $1.09T | 38.9 | 28.4 | 13.7 | +47.7% |
| Amgen | $442.30 | −0.12% | $239.00B | 27.5 | 18.9 | 6.3 | +9.7% |
| Alnylam Pharmaceuticals | $265.20 | −0.74% | $35.78B | 45.2 | 31.5 | 7.4 | +66.9% |
| Median | 33.2 | 23.6 | 6.9 | +28.7% |